STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer. Participants will receive one dose of Pluvicto, followed by radiation about 6 weeks later. Radiation therapy will be completed in 5 treatments over the period of 2 weeks. A second dose of Pluvicto will be given 6 weeks after radiation is complete. Some participants may also receive a third dose of Pluvicto, and t

Trial Details

NCT ID
NCT06574880
Phase
PHASE1 / PHASE2
Sponsor
Angela Y. Jia, MD PhD
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Lu-PSMA-617
  • 5-fraction Stereotactic Body Radiation Therapy (SBRT)
Locations (sample)
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Participant must be ≥ 18 years of age.
  • ECOG performance status ≤ 1
  • Histologic confirmation of prostate adenocarcinoma of the prostate
  • PSMA avid disease on PSMA PET/CT, where the tumor in the prostate has SUVmax ≥ 10.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →